New Possibilities for Cancer Immunotherapy Discovered Through Cancer Vaccines

Jihan Lin

doi:10.54097/rxtkht22

Authors

Jihan Lin

DOI:

https://doi.org/10.54097/rxtkht22

Keywords:

Cancer immunotherapy, canner vaccine, adjuvant.

Abstract

Cancer vaccine, a type of cancer immunotherapy, works by enhancing the identification and eradicating antigens, preventing cancer recurrence and stopping the growth or spread of tumors function. Because cancer vaccines are highly specific and therapeutically effective in preventing and treating cancer, it is gradually becoming the mainstay of cancer immunotherapy. First, some malignancies have relatively poor immunotherapy response rates, thus it's important to talk about ways to boost reactive T cell activity. In addition, how to combine cancer vaccines with other immunotherapies will be a challenge for cancer immunotherapy. In addition, how to apply adjuvants as well as novel materials as cancer vaccine delivery agents will also be the focus of subsequent cancer vaccine research. Currently, scientists aspire to use adjuvants to enhance the immunization effect of cancer vaccines and reduce their cost. This essay will concentrate on the cancer vaccine's mode of action, classification, benefits, and drawbacks, as well as its issues and possible uses. It will also offer suggestions for future cancer vaccine research and development.

Downloads

Download data is not yet available.

References

Morse MA, Gwin WR 3rd, Mitchell DA. Vaccine Therapies for Cancer: Then and Now. Target Oncol. 2021 Mar;16(2):121-152. doi: 10.1007/s11523-020-00788-w. Epub 2021 Jan 29. PMID: 33512679; PMCID: PMC7845582.

CHEN Y M，LIU Y C，ZHANG G P，et al． Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic［J］． Virus Ｒes，2016，220: 97-103

Liu Yun,Qiao Jiajia,Li Fang et al.Research progress of HPV vaccine[J]. Journal of Jilin Medical College,2022,43(04):286-289.DOI:10.13845/j.cnki.issn1673-2995.2022.04.020.

SONG Fang. Prevention of cervical cancer with instructions for HPV vaccine use[J]. Cancer Progress,2020,18(22):2286+2299.

oerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.

in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.

had weeks. All the cells for the treatment of melanoma vaccine research [D]. Qingdao university, 2023. The DOI: 10.27262 /, dc nki. Gqdau. 2022.000813.

Zhu SY, Yu KD. Breast Cancer Vaccines: Disappointing or Promising? Front Immunol. 2022 Jan 28;13:828386. doi: 10.3389/fimmu.2022.828386. PMID: 35154149; PMCID: PMC8831788.

Butterfield LH. Cancer Vaccines. BMJ (2015) 350:h988. doi: 10.1136/bmj.h988

Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL. Therapeutic Breast Cancer Vaccines: A New Strategy for Early-Stage Disease. BioDrugs (2009) 23:277–87. doi: 10.2165/11313490-000000000-00000

Al-Awadhi A, Lee Murray J, Ibrahim NK. Developing Anti-HER2 Vaccines:Breast Cancer Experience. Int J Cancer (2018) 143:2126–32. doi: 10.1002/ijc.31551

Milani A, Sangiolo D, Montemurro F, Aglietta M, Valabrega G. Active Immunotherapy in HER2 Overexpressing Breast Cancer: Current Status and Future Perspectives. Ann Oncol (2013) 24:1740–8. doi: 10.1093/annonc/mdt133

Dols A, Smith JW2nd, Meijer SL, Fox BA, Hu HM, Walker E, et al.Vaccination of Women With Metastatic Breast Cancer, Using aCostimulatory Gene (CD80)-Modified, HLA-A2-Matched, Allogeneic,Breast Cancer Cell Line: Clinical and Immunological Results. Hum GeneTher (2003) 14:1117–23. doi: 10.1089/104303403322124828

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination With Irradiated Tumor Cells Engineered to Secrete MurineGranulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity. Proc Natl Acad Sci U SA (1993) 90:3539–43. doi: 10.1073/pnas.90.8.3539

Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA Vaccine for Cancer Immunotherapy. Hum Vaccin Immunother (2014) 10:3153–64.doi: 10.4161/21645515.2014.980686

Ladjemi MZ, Jacot W, Chardes T, Pelegrin A, Navarro-Teulon I. Anti-HER2 Vaccines: New Prospects for Breast Cancer Therapy. Cancer Immunol Immunother (2010) 59:1295–312. doi: 10.1007/s00262-010-0869-2

72. Lentz BR. PEG as a Tool to Gain Insight Into Membrane Fusion. Eur Biophys

XIE Huicong,WANG Tingting,LIU Jiankai. Adsorption of aluminum adjuvant and its application in vaccines[J]. Advances in Microbiology Immunology,2023,51(02):76-81.DOI:10.13309/j.cnki.pmi.2023.02.011.

XU Yinyin,GU Zuhui,QIAN Hai. Progress in the study of nascent